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Abstract
Introduction: Monocyte-derived dendritic cells (DCs) are currently under extensive evaluation as cell vaccines for cancer
treatment. Many protocols regarding DCs generation in vitro with different protein components, especially autologous pro-
teins, have been described. On the other hand, active tumor-derived factors in patients’ serum could impair monocytes,
which might result in their abrogated differentiation into DCs in vitro.
Materials and Methods: Autologous DCs from non-small-cell lung cancer (NSCLC)-bearing patients were generated in dif-
ferent culture microenvironments. Peripheral blood mononuclear cells (PBMCs) were cultured in the presence of inter-
leukin-4 and granulocyte-monocyte-stimulating factor with supplementation of 10% autologous serum, 10% allogenic
serum, or 2% human albumin. The course of apoptosis, phagocytic ability, and the immunophenotype of the generated DCs
were analyzed using flow cytometric methods.
Results: After 48 h of culture, we found a lower percentage of CD1a+/CD14+ and a higher percentage of CD1a+/CD14– cells
in the culture supplemented with human albumin than in the cultures supplemented with serums. The lowest CD14 antigen
expression was found in the human albumin-supplemented 48-h cultures. After 48 h in the cultures carried out with human
albumin we found significantly higher percentages of AV+/PI+ cells and AV–/PI+ cells than in cultures supplemented with
autologous or allogenic serum. We also noted that the expression of FITC-dextran after 4 and 24 h of incubation was sig-
nificantly higher in the cultures supplemented with both serums than in the HA-SC. The percentage of semi-mature DCs
and of CD83 expression was lowest in the culture supplemented with 2% human albumin.
Conclusions: The kind of culture supplementation had a great impact on the apoptosis of cultured PBMCs. It could also influ-
ence the yield of monocyte-derived DCs. It was also confirmed that autologous and allogenic serums provide suitable
microenvironments for the generation of autologous DCs from NSCLC patients. The choice of culture supplementation for
DC generation is still unsolved and further studies should be undertaken.
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Abbreviations: AlloS-SC – allogenic serum-supplemented culture, APC – antigen-presenting cell, AutoS-SC – autologous
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iodide, IL-4 – interleukin-4, PBS – phosphate-buffered saline.
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INTRODUCTION
Lung cancer has the highest mortality rate amongst
men and women in western countries [4, 47]. Non-small-
-cell lung cancer (NSCLC), which includes adenocarci-
noma, squamous cell carcinoma, and giant cell carcino-
ma, comprises the majority of cases and is refractory to
conventional therapeutic modalities [4, 19, 47]. About
50% of NSCLC patients have stage IV disease at the
time of diagnosis and their median survival rate seldom
exceeds 6–9 months [19]. What is more, stages IIIB and
IV, which preclude surgical therapy, account for 70% of
all cases. Chemotherapy and radiotherapy applied to
that type of cancer are of low efficacy [4, 19, 24, 48]. The
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development of novel therapies for the treatment of
NSCLC. One of them is the administration of drugs that
suppress neoplastic cell proliferation by inhibition of the
epidermal growth factor receptor; another consists of
immunotherapy using unspecific factors that stimulate
the immune system, such as BCG vaccine, cytokines
which modulate the immunological response, neoplastic
antigens, and immune system cells [4, 19, 47]. There
have been many attempts to treat NSCLC patients with
cellular therapies, such as lymphokine-activated killer
cells or tumor-infiltrating lymphocytes, although results
have not been encouraging [4, 47, 50]. 
The discovery of dendritic cells (DCs) as profession-
al antigen-presenting cells (APCs) opened up new pos-
sibilities for their use in the development of cancer vac-
cines [10, 17, 20, 28, 38, 41, 49]. The principal purpose of
DC-based immunotherapy is to induce an antigen-spe-
cific immune response [20, 38]. The effector arm of anti-
-tumor immunity are CD4+ and CD8+ cells, which can
only recognize antigen when it is presented by APCs [17,
26, 38]. Owing to their unique properties, DCs, which
are the most potent APCs, are considered attractive
adjuvants in such immunotherapy [30, 38]. The prepara-
tion of a DCs vaccine comprises of the generation of DCs
from CD34+ precursor cells or monocytes, loading the
generated DCs with specific tumor antigens and, finally,
administration of the vaccine to the patient [10, 26, 30,
41]. Upon administration, the DCs should migrate to
secondary lymphoid organs and induce an antigen-spe-
cific immune response [17, 30]. DC-based cancer vac-
cines are used in patients with melanomas, myelomas,
prostate cancers, renal cancers, breast cancers, ovarian
cancers, and gastrointestinal cancers [10, 20, 26, 28, 38]. 
It is well known that in tumor-bearing hosts the
immune system frequently does not react to the tumors
[8, 15, 32, 45]. The tumoral microenvironment is usually
referred to as a “black hole”, where the mechanisms
which impair immune responses are not clearly identi-
fied [6, 18, 26, 32]. Clinical observations showed that
DCs possess the ability to migrate directly to a neoplas-
tic site, but it is still not clear why they are unable to
induce an efficient immune response [37, 42]. A growing
body of evidence suggests that autologous DCs in a can-
cer-bearing host are not fully competent, which could
account for the decreasing, or even obstructive, efficien-
cy of vaccination [10, 18, 22, 23, 26, 31]. How strongly
could tumor-derived factors inhibit the host immune
system?
With the above problems in mind, the aim of the
present study was to verify the ability to generate in vitro
DCs from NSCLC patients. The cultures were prepared
with an addition of 10% autologous serum from the
patients to create a microenvironment resembling the in
vivo appearance [12]. DCs were also generated in medi-
um supplemented with 2% human albumin to avoid the
possible inhibitory effect of the tumor microenviron-
ment [2]. Additionally, a generation with healthy human
serum was cultured to establish the influence of physio-
logical serum on DCs cultures. These methodologies
could be conducive to improving the methods of gener-
ating autologous DCs from NSCLC patients and to
adopting them in future immunotherapy.
MATERIALS AND METHODS
Clinical characteristic of the lung cancer patients
The study population comprised of 14 NSCLC sub-
jects (mean age: 61.75±9.92 years). Confirmation of the
histopathologic type of lung cancer was obtained for all
patients. Laboratory tests, chest X-rays, computed
tomography, ultrasonography, and bronchoscopy were
used for the evaluation of the lung cancer stage and type
of disease manifestation (Table 1). Stages from I to IIIA
were specified as local disease, whereas stages IIIB and
IV were specified as generalized lung cancer. Owing to
the small number of examined patients, this division was
applied in the statistical analysis [1].
Preparation of serum
Autologous serum was obtained by centrifugation
(3000 rpm/10 min.) of peripheral blood samples taken
from each patient, which were then frozen in aliquots
(10 aliquots of 1 ml, 4 aliquots of 200 µl) at 80°C and
successively thawed when examined. Allogenic serum
obtained from 14, only AB healthy volunteers served as
controls. The serums were not mixed. The serum sam-
ples was used to supplement the culture medium and for
cytokine measurement using ELISA.
Generation of DCs
Peripheral blood was drawn from NSCLC patients
into heparinized tubes according to the protocols
accepted by the local ethics committee. Peripheral
blood mononuclear cells (PBMCs) were isolated by
density gradient centrifugation (Lymphoprep, Nyco-
med, Norway). Total mononuclear cell counts oscillated
between 33 and 54 millions cells. After isolation, the
PBMCs were resuspended in RPMI 1640 medium
(BioWhittaker, Belgium) supplemented with penicillin-
-streptomycin (1% v/v, Sigma, Germany), seeded in 6-
-well tissue culture plates in an appropriate culture
microenvironment, and left to adhere for 1.5 h at
37°C in a humidified 5% CO2 atmosphere. The follow-
ing culture systems were carried out: 1) human albumin-
supplemented cultures (HA-SC): PBMCs from patients
in medium containing 2% human albumin [2]; 2) autol-
ogous serum-supplemented culture (AutoS-SC):
PBMCs from patients in medium containing 10% autol-
ogous serum; 3) allogenic serum-supplemented culture
(AlloS-SC): PBMCs from patients in medium contain-
ing 10% allogenic serum from a healthy donor. After
the adherence time, non-adherent cells were removed
and the culture plates were washed with cold phosphate-
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chrom AG, Germany) to obtain a pure fraction of
adherent CD14+ monocytes. The adherent cells were
then cultured in an appropriate medium supplemented
with recombinant human interleukin (IL)-4 (500 IU/ml,
Strathmann, Germany) and recombinant human granu-
locyte-monocyte-stimulating factor (1000 IU/ml,
Gentaur, Belgium). The cells were fed every three days.
On the 5th day, recombinant human tumor necrosis fac-
tor α (50 ng/ml, Strathmann, Germany) was added to
induce terminal maturation of the generated DCs. On
day 7, at the end of the culture, the supernatants were
collected and the adherent cells were harvested by incu-
bation with a trypsin/EDTA solution (0.25%/0.02%,
Biochrom AG, Germany). The obtained mature DCs
were washed in PBS without Ca2+ and Mg2+ and resus-
pended prior to immunophenotyping. The yield of cul-
tured DCs was 3–4% of the initial PBMC counts.
Phagocytosis assay
To measure the phagocytic activity of the generated
DCs, 5-day cultures in the aforementioned systems were
also carried out. At the end of the culture, the generat-
ed immature DCs were resuspended in RPMI 1640 and
incubated with FITC-dextran (ICN, Germany) at a con-
centration of 1 mg/ml of medium at 37°C for 4 and
24 h and at 4°C for 4 h. The incubations were stopped
by adding cold RPMI 1640. The cells were washed twice
with cold RPMI 1640 and immediately analyzed by flow
cytometry.
Apoptosis analysis in the course of the cell cultures 
For quantification of the cells undergoing early pro-
grammed cell death, an annexin V (AV) and propidium
iodide (PI) apoptosis detection kit (R&D, USA) was
utilized according to the manufacture’s protocol. The
cells were cultured in the above systems and then
removed from the culture plates after 48 and 96 h of
incubation. Freshly isolated PBMCs were also exam-
ined. The cells were washed with PBS without Ca2+ and
Mg2+ and resuspended in the binding buffer provided.
AV (FITC-conjugated) and specific monoclonal anti-
bodies (anti-CD14 TC-conjugated and anti-CD1a PE-
-conjugated, Caltag, USA) were added. The cells were
incubated for 15 min at room temperature in the dark.
PI was added in the last 5 min of incubation to the tubes
containing only AV; then the cells were analyzed by flow
cytometry.
Immunophenotyping of generated DCs
To characterize the phenotype of the generated
DCs, the following panel of FITC-, PE-, and TC-conju-
gated monoclonal antibodies (Caltag, USA) was used:
isotype control mouse anti-human IgG1/IgG2/IgG2a,
mouse anti-human CD45/CD14, mouse anti-human
CD83/CD1a/HLA-DR, and mouse anti-human CD80/
/CD86/HLA-DR.
The cells were incubated for 20 min in the dark and
then washed in PBS without Ca2+ and Mg2+. The cells
were analyzed using a FACSCalibur flow cytometer
(Becton Dickinson, USA) equipped with a 488-nm
argon laser. An acquisition gate was established based
on forward scatter (FSC) and side scatter (SSC) that
included only the monocyte population (mononuclear
cells) and excluded lymphocytes. After acquisition, the
cells were analyzed with CellQuest Software.
ELISA analysis of IL-10 level in the patients’ serum
The level of IL-10 was measured in the patients’
serum using the Quantikine HS Human IL-10 ELISA
Kit (R&D Systems, USA) and ELX 800 equipment (Bio-
Tek Instruments, USA).
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Table 1. Clinical characteristic of examined patients
No.       Age      Gender        Disease TNM           Stage Localization Prospects             Leukocyte count
(years)
1 51 M SCC T4N3M1 IV right, central death above normal
2 50 M SCC T2N0M0 I right, central chemotherapy normal
3 65 M SCC T3N2M0 IIIA left, central chemotherapy normal
45 3 M A C T 4N2M1 IV left, central death normal
5 58 M SCC T2N1M0 II left, central surgery above normal
6 75 M SCC T3N2M0 IIIA left, central surgery above normal
7 53 F other* T3N3M0 IIIB right, peripheral death normal
87 0 M A C T 4N2M0 IIIB left, central chemotherapy normal
9 76 M other** T4N2M0 IIIB right, central chemotherapy above normal
10 78 M other** T4N3M0 IIIB right, peripheral chemotherapy normal
11 62 M SCC T4N1M0 IIIB right, central chemotherapy above normal
12 70 M GCC T2N1M0 II left, peripheral surgery normal
13 63 M SCC T4N3M0 IIIB left, central chemotherapy above normal
14 67 M SCC T3N1M0 IIIA left, central surgery normal
SCC – squamous cell carcinoma, AC – adenocarcinoma, GCC – giant cell carcinoma, other – including *low-differentiated
NSCLC and **unclassified NSCLC, TNM – classification of tumors [4]. 
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The data are presented as the mean value ±SD. To
evaluate the statistical significance, the Mann-Whitney 
U-test was used to compare unpaired group data. The
Wilcoxon matched pairs test was applied for comparing
two variables. We also applied the non-parametric
Kolmogorow-Smirnow test to compare the two groups.
The Spearman correlation test was used for correlating
observations. A level of p<0.05 was considered significant.
RESULTS
The influence of culture supplementation 
on the expressions of CD1a and CD14 antigens 
as well as cell apoptosis
In this investigation the cell population was analyzed
using an assay for phosphatidylserine expression as orig-
inally developed by Vermes et al. [44]. We defined early
apoptotic cells as AV+/PI–, late apoptotic cells and
necrotic cells as AV+/PI+, and dead cells as AV–/PI+.
A representative cytometric analysis is shown in Fig. 1. 
After 48 h of culture, we found a significantly
(p<0.05) lower percentage of CD1a+/CD14+ cells in the
culture supplemented with human albumin than in the
cultures supplemented with autologous or allogenic
serum. Moreover, in the culture with human albumin we
found a significantly (p<0.05) higher percentage of
CD1a+/CD14– cells than in the cultures carried out with
the addition of autologous or allogenic serum (Table 2). 
The expression of CD14 antigen was significantly
higher on freshly isolated cells than on cells cultured in
all types of medium. In the 96-h cultures a small popu-
lation of cells, resembling macrophages, with a high
expression of CD14 antigen and high values of the FSC
and SSC parameters, appeared. These macrophage-like
cells were also found at the end of the DC generation
(Fig. 2). The lowest CD14 antigen expression was found
in the human albumin-supplemented 48-h cultures.
A significant (p<0.05) increase in CD1a antigen expres-
sion was observed between 48 and 96 h in all cultures.
After 48 h of culture, the percentage of AV+ cells
among the populations of CD1a+/CD14+ cells and
CD1a+/CD14– cells was significantly higher in the HA-
-SCs than in the autologous or AlloS-SC. More interest-
ingly, in the cultures carried out with human albumin we
found significantly higher percentages of AV+/PI+ cells
and AV–/PI+ cells than in cultures supplemented with
autologous or allogenic serum (Table 2, Fig. 3). 
In HA-SC after 96 h of incubation we found a sig-
nificantly higher percentage of AV+ cells amongst
CD1a+/CD14+ and CD1a+/CD14– cell populations in
comparison with AutoS-SC and AlloS-SC. We also
noted a significantly higher percentage of AV+/PI+ cells
in culture supplemented with human albumin compared
with the two other culture systems.
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Fig. 1. Representative cytometry analysis of AV and PI expression on generated mononuclear cells after 48 and 96 h of incubation. A – cul-
ture supplemented with autologous serum, B – culture supplemented with allogenic serum, C – culture supplemented with human albumin.
Dot plots correspond to the gated cells from region R1.
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examined parameters between the cultures supplement-
ed with autologous serum and allogenic serum after 48
and 96 h of incubation. The percentages of cells gener-
ated in all the cultures are shown in Table 2 and Fig. 3.
Relationship between cancer stage and the expressions 
of CD1a and CD14 antigens as well as cell apoptosis
in differently supplemented cultures
After 96 h of incubation in AutoS-SC and AlloS-SC,
a significantly higher percentage of double-positive
CD1a+/CD14+ cells and lower percentage of CD1a+/
/CD14– cells were found in patients with advanced dis-
ease than in subjects suffering from earlier stages of
lung cancer. Interestingly, a significantly lower percent-
age of AV+/PI+ and AV+/PI– cells were detected in
patients with advanced stages of lung cancer than in
patients with local tumor growth. The percentages of
examined cells were similar in both groups of patients in
the cultures performed with human albumin.
There were significant negative correlations between
the percentages of CD1a+/CD14– cells and AV+/PI–
cells in AutoS-SC and AlloS-SC after 48 and 96 h of
incubation in all the patients (R=–0.70, p<0.05). Also,
after 96 h of incubation in AutoS-SC the percentages of
CD1a+/CD14– cells and of AV+/PI– cells correlated sig-
nificantly negatively with patient leukocytosis.
Serum IL-10 level and its influence on the expressions 
of CD1a and CD14 antigens and cell apoptosis
The total mean level of IL-10 in the patients’ serum
was 6.57±3.51 pg/ml. Serum IL-10 level was significantly
higher (p=0.01) in NSCLC patients than in control sub-
jects (2.957±2.177 pg/ml). The IL-10 concentration was
similar in patients with different clinical stages of the
disease.
After 48 h of culture with autologous serum supple-
mentation we found a significant negative correlation
between the percentage of CD1a+/CD14+ cells and the
level of IL-10 (R=–0.69, p<0.05). We also noted posi-
tive correlation between the IL-10 level and the per-
centage of CD1a+/CD14– cells (R=0.69, p<0.05). The
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Table 2. Characteristics of cells generated before culture and after 48 h and 96 h of culture supplemented with autologous serum,
allogenic serum, and human albumin
Percentage of  Before culture 
Autologous serum Allogenic serum Human albumin
generated cells 48 h 96 h 48 h 96 h 48 h 96 h
CD1a+/CD14+ 79.72 ±15.33 87.67 ±8.83 84.66 ±13.69 88.84 ±9.15 82.48 ±15.2 79.45 ±8.38 76.02 ±22.07
CD1a+/CD14– 7.07 ±7.13 7.57 ±7.44 8.22 ±8.37 6.7 ±4.43 10.74 ±10.54 13.46 ±6.5 15.01 ±17.29
AV+/CD1a+/CD14+ 3.59 ±2.13 25.55 ±8.35 33.95 ±23.36 25.68 ±13.93 32.06 ±22.16 43.6 ±16.36 49.9 ±18.84
AV+/CD1a+/CD14– 2.5 ±1.54 28.54 ±12.99 18.82 ±13.56 27.95 ±14.1 20.02 ±7.5 49.8 ±14.8 39.8 ±18.4
AV+/PI– 0.64 ±1.0 8.49 ±5.93 6.58 ±5.43 10.13 ±9.24 7.93 ±4.73 6.35 ±4.31 9.14 ±5.03
AV+/PI+ 2.16 ±1.72 12.33 ±7.79 24.04 ±12.07 12.79 ±8.96 22.8 ±9.94 40.62 ±15.8 35.34 ±12.9
AV–/PI+ 2.19 ±0.78 2.97 ±2.86   6.88 ±3.74 2.42 ±2.26 11.19 ±8.56 6.5 ±3.77 9.68 ±9.31
MFI CD14 681 ±454 151.1 ±64.27 206.14 ±181.1 152.18 ±66.8 146.03 ±82.9 73.63 ±39.3 132.05 ±91.46
MFI CD1a 98.8 ±70.65 64.9 ±13.98 118.41 ±64.6 68.8 ±16.17 110.7 ±42.4 68.32 ±33.84 139.98 ±98.6
MFI – mean fluorescence intensity.
Fig. 2. Macrophage-like cells and DCs generated after 7-day cul-
ture supplemented with 10% autologous serum. The cells were
stained by the May-Grünwald Giemsa method.
Fig. 3. Percentages of apoptotic, late apoptotic, and necrotic cells
before and after 48 h of culture in different microenvironments.
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centage of AV+/PI– cells (R=–0.60, p=0.11) and non-
-significantly positively with the percentage of AV+/PI+
cells (R=0.57, p=0.14). There were no significant cor-
relations after 96 h of culture with autologous serum
supplementation.
Engulfment of FITC-dextran by generated immature DCs
To test the phagocytic function of immature DCs
generated in the above three culture systems, we evalu-
ated the uptake of FITC-dextran by DCs using flow
cytometry. The results are presented as the mean fluo-
rescence intensity of dextran-positive cells and are
shown in Table 3. The flow cytometric analysis of FITC-
-dextran engulfment by generated cells is shown in Fig. 4.
In all the cultures we found a significantly (p<0.001)
higher expression of FITC-dextran in cultured cells
after 4 and 24 h of incubation than in control cells incu-
bated at 4°C. We also noted that the expression of
FITC-dextran after 4 and 24 h of incubation was signif-
icantly (p<0.05) higher in the cultures supplemented
with autologous and allogenic serum than in the HA-
-SC. There were no significant differences between cells
derived from autologous and AlloS-SCs in FITC-dex-
tran expression.
Immunophenotype of generated DCs
The generated DCs were divided into two groups
according to the expressions of leukocyte-monocyte-
-specific markers: double-positive cells (CD45+/CD14+),
which did not lose their monocytic attribute during the
cultures, and CD45+/CD14– cells, which appeared to
lose their monocytic feature and turn into DCs. In all
the cultures we observed low percentages of
CD45+/CD14+ cells and high percentages of CD45+/
/CD14– cells. We did not find any significant differences
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Table 3. Expression of FITC-dextran phagocytozed by immature DCs cultured with autologous serum, allogenic serum, and
human albumin supplemented cultures
Culture microenvironment Cells incubated at 4°C Cells incubated at 37°C for 4 h Cells incubated at 37°C for 24 h
10% Autologous serum 15.1±10 MFI 28.29±11.95 MFI 37.39±17.4 MFI
10% Allogenic serum 15.55±12.92 MFI 25.47±11.7 MFI 38.02±18.72 MFI
2% Human albumin 18.78±22.56 MFI 20.69±9.13 MFI 24.9±11.42 MFI
MFI – mean fluorescence intensity.
Fig. 4. Phagocytosis of FITC-dextran particles by immature DCs generated from representative patients in: A – AutoS-SC, B – AlloS-SC and
C – HA-SC, after 4 and 24 h of incubation. Dotted line: control cells incubated at 4°C, continuous line: cells incubated at 37°C. Histograms
correspond to the gated cells from region R1 and presented mean fluorescent intensity of FITC-dextran and cell counts.
AB C
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expression in all the cultures. 
In all the cultures we observed cells with typical DC
morphology (Fig. 5). According to the expression of
CD1a antigen, we recognized semi-mature DCs as
CD83+/CD1a+/HLA-DR+ cells and mature DCs as
CD83+/CD1a–/HLA-DR+ cells [36, 52]. The percentage
of semi-mature DCs and of CD83 expression was lowest
in the culture supplemented with 2% human albumin.
Moreover, we found a significantly higher percentage of
CD83+/CD1a+/HLA-DR+ cells and a significantly high-
er expression of CD83 antigen in the culture supple-
mented with autologous serum than in the culture with
human albumin. 
We also divided the generated DCs according to the
expressions of co-stimulatory molecules into CD80+/
/CD86+/HLA-DR+ cells and CD80+/CD86–/HLA-DR+
cells [11]. There were no differences among all the cul-
tures in the percentages of these cells. A small popula-
tion of CD80–/CD86+/HLA-DR+ cells in all the exam-
ined microenvironments was observed in only one
patient (no. 3). A significantly (p<0.001) higher expres-
sion of CD86 antigen was observed on cells from AutoS-
-SC and from AlloS-SC compared with cells from HA-
-SC. The immunophenotype analyses of the generated
DCs are presented in Table 4.
Comparison of patients’ clinical stage and immuno-
phenotype of generated DCs
In the culture supplemented with autologous serum
we observed a significantly (p<0.001) lower expression
of CD14 antigen on DCs generated from the subjects in
earlier stages than from those with advanced stages of
disease. In the patients with localized lung cancer, the
expressions of the HLA-DR and CD86 antigens were
non-significantly higher than in the patients with
advanced disease. CD86 antigen expression significantly
positively (R=0.67, p<0.05) correlated with IL-10 level.
Dendritic cells generated in AlloS-SC from patients
with earlier stages of lung cancer were characterized by
a significantly (p<0.05) higher expression of HLA-DR
and a significantly (p<0.05) lower expression of CD80
antigens than DCs generated from patients with
advanced disease. We also found a non-significantly
higher expression of CD14 antigen on DCs from
patients with advanced stages than from those with
localized lung cancer. Interestingly, in the culture sup-
plemented with human albumin, the expression of
CD14 antigen was also non-significantly higher in
patients with advanced stages than in patients with ear-
lier stages of the disease.
DISCUSSION
Currently, monocyte-derived DCs are becoming
widely used as cell vaccines for cancer treatment [10, 26,
38, 49]. The requirement for optimized and standard-
ized protocols for the generation of DCs on a large scale
has led to the description of several protocols [2, 17, 21,
33, 34, 49]. In many clinical studies, autologous plasma,
fetal calf serum (FCS), allogenic AB plasma, and human
albumin were used as serum or protein components to
support the generation of DCs [2, 12, 21, 26]. The use of
FCS in cultures to prepare DCs precludes their practical
application, because FCS contains xenogenic proteins
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Fig. 5. Morphology of generated mature DCs in culture: A – sup-
plemented with 10% autologous serum; B – 10% allogenic serum;
C – 2% human albumin. The cells were stained by the May-
-Grünwald Giemsa method.
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DCs [26]. It is possible to use allogenic human plasma,
but this raises the possibility of the transmission of infec-
tious pathogens [21]. It has been proposed that human
albumin is a kind of non-antigen culture substrate and
can provide the “clearest” culture microenvironment,
but one that is destitute of natural growth factors [2].
These limitations suggest that autologous plasma or
serum would be a less hazardous choice for DCs gener-
ation [12, 34]. Of course, this situation is suitable for
healthy volunteers. Unfortunately, there is still insuffi-
cient information about the influence of serum from
cancer patients on DCs generation from CD14+ mono-
cytes. The active tumor-derived factors in patients’
serum could impair monocytes, which might result in
their abrogated differentiation into DCs in vitro [1, 22,
31, 35, 40]. The questions that then arise are whether
tumors affect DCs generation and whether it is possible
to reverse the restraining effect of the tumor microenvi-
ronment under in vitro conditions. To answer the ques-
tions, the aim of this study was to verify the ability to
generate DCs from NSCLC-bearing patients in cultures
supplemented with autologous serum, allogenic serum,
and human albumin.
In this study we first tried to evaluate the fate of cul-
tured monocytes and the induction of apoptosis on early
differentiated cells. It is known that the induction of
apoptosis does not occur only by direct contact with
tumor cells [23, 46]. It has been demonstrated that
murine DCs treated with supernatants from tumor cell
lines undergo apoptosis [46]. By combining AV, which
was shown [43] to have a high affinity for phos-
phatidylserine, with PI we discriminated between early
apoptotic cells (AV+/PI–), late apoptotic cells and
necrotic cells (AV+/PI+), and death cells (AV–/PI+)
among the mononuclear cells in different culture
microenvironments. We found that the highest percent-
age of AV+ cells as well as the highest percentages of
AV+/PI+ and AV–/PI+ cells were in those cultured for
48 h in human albumin. The highest percentages of
apoptotic and necrotic cells were also detected after 96
h in the aforementioned cultures’ microenvironments.
Moreover, the highest percentage of CD1a+/CD14–
cells was found in the HA-SC cells. Unexpectedly, this
pattern also appeared when we compared the subtypes
of cells from AutoS-SC from patients in different stages
of lung cancer. The percentages of AV+ cells as well as
the percentage of CD1a+/CD14– cells were highest in
patients with early stages of lung cancer. We noted neg-
ative correlation between the percentages of
CD1a+/CD14– and AV+/PI– cells as well as negative cor-
relation between patients’ leukocytosis and the percent-
ages of the above cells.
It is known that monocytes lose their CD14 antigen
expression during their differentiation into DCs and
turn into a CD1a+/CD14– cell population [5, 26, 34]. In
our experiment schedule we found a significantly
decreasing expression of CD14 antigen in all the per-
formed cultures, but most of all in the HA-SCs. In con-
nection with the apoptosis levels in the human albumin
culture after 48 and 96 h, we can suggest that the
decrease in CD14 antigen expression is caused by the
cells dying rather than their differentiation into imma-
ture DCs. CD14 antigen could be peeled off by apop-
totic cells. This could be confirmed by results obtained
in cultures performed with autologous or allogenic
serum supplementation. In the aforementioned culture
conditions we found lower percentages of apoptotic and
necrotic cells as well as a higher expression of CD14
antigen compared with the HA-SCs. On the other hand,
Avila-Moreno et al. [3] found that soluble factors from
lung cancer cell lines caused an increase in the expres-
sion of myelomonocytic markers and altered the differ-
entiation of monocytes in vitro from DCs to macro-
phages. In our study we also observed macrophage-like
cells in AutoS-SC and AlloS-SC, but the percentage of
these cells was very small. The results presented here let
us speculate that autologous serum, in the case of lung
cancer, provides a better culture microenvironment for
the generation of autologous cells, which seem to be
prevented from early apoptosis.
The cause of this phenomenon remains unclear. It
has been shown repeatedly that factors which possess
a strong inhibitory capacity can be detected in the serum
of cancer-bearing patients [22, 23, 29]. Some trials have
been carried with tumor culture supernatants (TSN).
Kiertscher et al. [23] have shown a reduced capacity to
produce IL-12 by DCs generated with TSN supplemen-
tation. However, Marten et al. [27] have shown the
strong stimulatory activity of DCs generated with
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Table 4. Immunophenotype analysis of DCs generated in different culture microenvironments
Immunophenotype of DCs (%) 10% Autologous serum 10% Allogenic serum 2% Human albumin
CD45+/CD14– 81.9±18.13 84.82±13.04 78.74±17.73
CD45+/CD14+ 13.84±15.7 12.33±11.9 17.8±16.8
CD83+/CD1a+ 52.69±41.01 46.27±38.58 64.03±32.86
HLA-DR+ cells among CD83+/CD1a+ DCs 98.53±2.51 97.46±4.26 90.25±25.01
CD83+/CD1a– 35.81±42.64 37.19±43.1 29.17±35.12
HLA-DR+ cells among CD83+/CD1a– 87.56±18.3 91.51±10.78 83.29±21.11
CD80+/CD86+ 82.82±16.66 87.76±13.21 80.66±23.14
HLA-DR+ cells among CD80+/CD86+ 86.73±17.37 81.31±22.04 86.62±21.73
CD80+/CD86– 10.28±14.31 5.29±8.04 15.88±23.66
HLA-DR+ cells among CD80+/CD86– 72.25±28.79 71.79±8.04 64.41±35.96
press-6.qxd  11/28/07 3:02 PM  Page 412patient-derived CA-19-9-antigen-containing serum. The
HA-SCs are a clear environment for DCs generation,
but it seems to be devoid of important cell viability fac-
tors. Interestingly, Araki et al. [2] generated efficient
DCs from CD14+ monocytes of healthy volunteers in
the presence of human albumin. It is widely known that
many cytokines or immunosuppressive cancer-derived
factors detected in the serum of cancer patients inter-
fered in many ways with each stage of the generation of
DCs [7, 14, 16, 22, 29, 35, 39]. It has been suggested that
IL-10 is the most important inhibitory factor responsible
for impaired immune responses in the peripheral blood
of cancer-bearing patients [7, 13, 14]. A variety of
human tumors produce IL-10. The mRNA for IL-10 was
detected in metastatic melanoma and renal, ovarian,
and basal cell carcinomas [25, 32]. We have also shown
that the level of IL-10 detected in patients’ serum posi-
tively correlated with the percentage of CD1a+/CD14–
cells and AV+/PI+ cells in AutoS-SC. 
It should be noted that in most cancer patients the
inflammation process coexists with the development of
neoplasm, which could result in a greater release of
immunomodulatory factors [9]. Our results suggest that
the progression of lung cancer had a beneficial impact
on the vitality of mononuclear cells in short-terminated
cultures. In light of the present results, the restraining
effect of tumor-derived factors in autologous serum
from NSCLC patients appears to be overestimated. We
propose that generalized lung cancer does not exert as
strong an inhibitory pressure on autologous DCs gener-
ation as suspected up to now.
Some literature data concerned the generation of
DCs from patients with advanced cancer [26, 29, 33, 51].
Menetrier-Caux et al. [29] demonstrated that tumor
cells produce factors which could significantly inhibit
the differentiation of hematopoietic precursors and, in
turn, DCs generation. It has been shown repeatedly that
the expressions of CD83 and CD86, human DC-related
markers, decreased in DCs cultures co-incubated with
supernatant from human tumor cells [7, 13]. In this
study we estimated the presence of mature
CD83+/CD1a– DCs with co-expression of costimulatory
molecules in all the cultures. Interestingly, the highest
expression of CD83 antigen was found in AutoS-SC.
These findings are contrary to those of Kiertscher et al.
[23], who had demonstrated that tumor culture super-
natants effectively suppress the function of monocyte-
and stem cell-derived DCs. Onishi et al. [31] showed
that monocyte-derived DCs from cancer patients pos-
sessed weaker antigen-presenting abilities than those
generated from healthy volunteers. In our study we
found that immature DCs generated in all the cultures
show phagocytic activity measured by dextran particle
engulfment. When we compared the culture microenvi-
ronments we found the highest level of FITC-dextran
fluorescence in cells generated with autologous and
allogenic serum supplementation. This confirms the
above thesis about the beneficial influence of autolo-
gous and allogenic serum on DCs generation.
To sum up, we have documented the course of the
apoptosis, phagocytic ability, and the immunopheno-
type of DCs generated in different culture microenvi-
ronments. First of all we can conclude that the kind of
culture supplementation had a great impact on the
apoptosis of generated DCs. It could also influence the
yield of monocyte-derived DCs, which should be exam-
ined in a further study. Secondly, we can confirm that
autologous and allogenic serums provide a suitable
microenvironment for the generation of autologous
DCs from NSCLC patients. Of course, further studies
should expand upon lymphocytic stimulation by gener-
ated DCs, which could provide an important insight into
the stimulatory activity of DCs. Also, the efficacy of DCs
generation from PBMCs of lung cancer patients should
be tested using serum-free media available commercial-
ly, such as CellGro DC. The choice of culture supple-
mentation for DCs generation is still unsolved and fur-
ther studies should be undertaken.
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